HCG
Healthcare Global Enterprises Limited
Each stock's 10,000-path forecast, rendered as light.
Healthcare Global Enterprises Limited (HCG) Stock Analysis & Case Study
Is HCG a good buy? The data-driven verdict.
Healthcare Global Enterprises Limited (HCG) trades at ₹676,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, Healthcare Global Enterprises Limited (HCG) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 209.0× earnings, ROE of 2.5%, a 60% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
HCG fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How HCG ranks against the 2,373 companies in our screener
- HCG's market cap of 10,091 Cr ranks in the 75th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- HCG's book value of ₹89 ranks in the 49th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- HCG's promoter holding of 64.2% ranks in the 61st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- HCG's 3-year profit (PAT) growth of -1.0% ranks in the 28th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- HCG's 3-year revenue growth of 15.0% ranks in the 63rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- HCG's debt-to-equity ratio of 1.30x is lower than 10% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is HCG overvalued? HCG P/E vs peers
HCG trades at 209.0× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
HCG share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of HCG history (12%/yr drift, 33%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| HCG 2027 | ₹490 | ₹735 | ₹1,102 | +9% |
| HCG 2028 | ₹451 | ₹799 | ₹1,414 | +18% |
| HCG 2029 | ₹425 | ₹868 | ₹1,773 | +28% |
| HCG 2030 | ₹417 | ₹944 | ₹2,135 | +40% |
| HCG 2031 | ₹412 | ₹1,026 | ₹2,555 | +52% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability HCG goes up, or doubles?
The bull case for HCG
- A 10,000-path probability model puts a 60% chance the price is higher in a year, with a median target of ₹735 (+9%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,773.
The bear case & risks
- HCG's P/E of 209.0x is lower than 5% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- HCG's return on equity of 2.5% ranks in the 21st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- HCG's Piotroski F-Score of 3/8 ranks in the 15th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹425.
HCG volatility & expected range, how bumpy is the ride?
Over the last 9.8 years HCG compounded at 12%/year with annualized volatility of 33%. That volatility implies a 1-year 80% range of ₹490-₹1,102, the honest backbone behind any single price target.
HCG price forecast, the full 60-month probability fan
HCG price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds HCG hits common targets within the simulated horizon?
Full multi-horizon detail on the HCG price target & forecast page.
HCG Piotroski F-Score: 3/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. HCG scores 3/8, weak on the financial-strength checks.
HCG MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy HCG with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| ZerodhaCHEAPEST | 29.90% | 3.3× |
| Groww | 30.05% | 3.3× |
| Dhan | 30.00% | 3.3× |
| Kotak Neo | 34.97% | 2.9× |
| Paytm Money | 30.43% | 3.3× |
| Pocketful | 30.35% | 3.3× |
| Anand RathiCHEAPEST | 29.90% | 3.3× |
| Bajaj Broking | 31.00% | 3.2× |
| Share India | 30.02% | 3.3× |
Compare every broker on the HCG MTF page.
About Healthcare Global Enterprises Limited: sector, index & market-cap context
Healthcare Global Enterprises Limited (HCG) is a small-cap NSE-listed company, with a market capitalisation of ₹10,091 Cr. See more stocks on our screener.
How the HCG Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Healthcare Global Enterprises Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
HCG analysis, FAQs
Is Healthcare Global Enterprises Limited (HCG) a good buy?
On the numbers, Healthcare Global Enterprises Limited (HCG) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 209.0× earnings, ROE of 2.5%, a 60% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is HCG overvalued or undervalued?
HCG trades at 209.0× earnings, expensive versus the ~22× long-run Nifty average.
What is the HCG share price target for 2031?
HCG's probability-weighted 2031 median target is ₹1,026, with an 80% range of ₹412-₹2,555 (10,000-path Monte-Carlo).
What is the probability HCG doubles in 5 years?
The modelled probability of HCG reaching ₹1,352 (2×) within 5 years is 35%.
What is the bull case for HCG?
A 10,000-path probability model puts a 60% chance the price is higher in a year, with a median target of ₹735 (+9%).
What are the risks in HCG?
HCG's P/E of 209.0x is lower than 5% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. HCG's return on equity of 2.5% ranks in the 21st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. HCG's Piotroski F-Score of 3/8 ranks in the 15th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.